Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty

Journal of Orthopaedic Science

Volumn 10, Issue 1, 2005, Pages 32-36

  Yamaguchi, Katsuyuki ^a   Masuhara, Kensaku ^b   Yamasaki, Satoshi ^b   Fuji, Takeshi ^b  

^a Kaizuka City Hospital   (Japan)

^b OSAKA KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

Bone mineral density; Cementless total hip arthroplasty; Dose response relationship; Etidronate; Stress shielding

Indexed keywords

CALCIUM CARBONATE; ETIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE STRESS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LOW DRUG DOSE; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TOTAL HIP PROSTHESIS; VITAMIN SUPPLEMENTATION;

EID: 13244277874     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00776-004-0854-8     Document Type: Article

References (21)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
2. Cortet B, Béra-Louville A, Gauthier P, et al. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. Effect of adding hormone replacement therapy. Joint Bone Spine 2001;68:410-15.
3. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
4. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone (NY) 1996;18:141-50.
5. Fujita T, Orimo H, Inoue T. A dose-finding study on osteoporosis of etidronate disodium (EHDP). Kiso to Rinsho (The Clinical Report) 1994;28:447-86 (in Japanese).
6. Gruen TA, McNeice GM, Amstutz HC. "Modes of failure" of cemented stem-type femoral components. A radiographic analysis of loosening. Clin Orthop 1979;141:17-27.
7. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:557-67.
8. Kiratli BJ, Checovich MM, McBeath AA, et al. Measurement of bone mineral density by dual-energy X-ray absorptiometry in patients with the Wisconsin hip, an uncemented femoral stem. J Arthroplasty 1996;11:184-93.
9. Massari L, Bagni B, Biscione R, et al. Periprosthetic bone density in uncemented femoral hip implants with proximal hydroxyapatite coating. Bull Hosp Jt Dis 1996;54:206-10.
10. Matsui M, Nakata K, Masuhara K, et al. The Metal-Cancellous Cementless Lübeck total hip arthroplasty. Five-to-nine-year results. J Bone Joint Surg [Br] 1998;80:404-10.
11. Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997;103:468-76.
12. Plötz W, Gradinger R, Rechl H, et al. Cementless prosthesis of the hip joint with "spongy metal" surface. A prospective study. Arch Orthop Trauma Surg 1992;111:102-9.
13. Pols HAP, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999;9: 461-8.
14. Skinner HB, Kim AS, Keyak JH, et al. Femoral prosthesis implantation induces changes in bone stress that depend on the extent of porous coating. J Orthop Res 1994;12:553-63.
15. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322:1265-71.
16. Sugano N, Saito S, Takaoka K, et al. Spongy metal Lübeck hip prostheses for osteoarthritis secondary to hip dysplasia. A 2-6-year follow-up study. J Arthroplasty 1994;9:253-62.
17. Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501.
18. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
19. Yamaguchi K, Masuhara K, Ohzono K, et al. Evaluation of periprosthetic bone-remodeling after cementless total hip arthroplasty. The influence of the extent of porous coating. J Bone Joint Surg [Am] 2000;82:1426-31.
20. Yamaguchi K, Masuhara K, Yamasaki S, et al. Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty. Bone (NY) 2003;33:144-9.
21. Yamaguchi K, Masuhara K, Yamasaki S, et al. Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty. Bone (NY) 2004;35:217-23.